Justine M. Tyler

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

C. R. Leemans, C. McConkey, T. Roques, 2019, The Lancet.

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer

S. Bhide, K. Harrington, T. Roques, 2016, BMC Cancer.

Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancer

C. Clark, E. Miles, C. Nutting, 2021, Physics and imaging in radiation oncology.

Inter-Observer Variation in Delineating the Pharyngeal Constrictor Muscle as Organ at Risk in Radiotherapy for Head and Neck Cancer

C. Nutting, D. Mcquaid, E. Hall, 2021, Frontiers in Oncology.

PO-0858: Development of dysphagia optimised IMRT for head and neck cancer treatment in the DARS trial

C. Nutting, D. Bernstein, K. Rooney, 2016 .

Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer.

S. Bhide, T. Roques, C. Nutting, 2020 .

An external dosimetry audit programme to credential static and rotational IMRT delivery for clinical trials quality assurance.

D. Eaton, Jonathan Lee, A. Carver, 2017, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.

S. Bhide, T. Roques, C. Nutting, 2023, The Lancet. Oncology.